Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 06 2017 - 8:30AM
Business Wire
Cerus Corporation (NASDAQ:CERS) announced today that,
on April 3, 2017, the compensation committee of the company's
board of directors granted 21 new non-executive employees options
to purchase an aggregate of 378,200 shares of the company's common
stock with a per share exercise price of $4.39, the closing
trading price of the company's common stock on the NASDAQ Global
Market on Monday, April 3, 2017. Each option has a ten-year term
and will vest over a four-year term, with one-eighth of the shares
subject to the option vesting after six months and the remaining
shares vesting in equal monthly increments.
The stock options were granted pursuant to Rule 5635(c)(4) of
the NASDAQ Listing Rules for equity grants to induce the new
employees to enter into employment with the company.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in
the field of blood transfusion safety. The INTERCEPT Blood System
is designed to reduce the risk of transfusion-transmitted
infections by inactivating a broad range of pathogens such as
viruses, bacteria and parasites that may be present in donated
blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile
Virus and bacteria, as well as emerging pathogens such as
chikungunya, malaria and dengue. Cerus currently markets and sells
the INTERCEPT Blood System for both platelets and plasma in the
United States, Europe, the Commonwealth of Independent States, the
Middle East and selected countries in other regions around the
world. The INTERCEPT red blood cell system is in clinical
development. See www.cerus.com for more information about
Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170406005446/en/
Cerus Corporation Contact:Lainie Corten - Vice President, Global
Marketing & Investor Relations(925) 288-6137ir@cerus.com
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2024 to May 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From May 2023 to May 2024